{Reference Type}: Journal Article
{Title}: [Comprehensive management guideline for breast cancer follow-up and healthcare (2022 edition)].
{Author}:  ; ;
{Journal}: Zhonghua Zhong Liu Za Zhi
{Volume}: 44
{Issue}: 1
{Year}: Jan 2022 23
暂无{DOI}: 10.3760/cma.j.cn112152-20211029-00798
{Abstract}: In recent years, with the emphasis on breast cancer screening and the improvement of standardized diagnosis and treatment, cure rate and survival time of breast cancer patients have been significantly improved in China. Accompanied by prolonged follow-up period, patients are facing increasing cancer and other related health issues, which calls for a more accurate and long-term follow-up plan and focus on broader health risks. Health issues on cardiovascular system, bone density, blood lipid and psychology caused by anti-cancer treatment, senescence or changes in hormone levels have become new challenges in the management of patients with breast cancer, not only affecting the life quality, but also impacting disease recurrence and death. Therefore, in addition to standardized treatment, scientific and standardized follow-up, comprehensive management of patients' concomitant diseases, interdisciplinary cooperation and holistic rehabilitation are also vital links to treatment. This could improve the therapeutic efficacy of anti-cancer treatment and the quality of life of patients. Based on the current landscape of treatment and follow-up of breast cancer patients in China, the experts committee updated the "Comprehensive Management Guideline for Breast Cancer Follow-up and Concomitant Diseases (2019 edition)" and revised it as "Guidelines for breast cancer follow-up and health management in China (2022 edition)" according to the latest literature and guidelines and medical advice from interdisciplinary experts. This new guideline is composed of four parts: path diagram, follow-up management, comprehensive healthcare management, and patient reported outcome. It aims to standardize the long-term follow-up of breast cancer patients, guide clinicians to actively provide comprehensive interdisciplinary healthcare management, and further improve the prognosis and life quality of breast cancer patients in China.<BR>近年来，随着对乳腺癌筛查的重视与规范化诊疗技术的提升，中国乳腺癌患者治愈率显著提高，患者生存时间显著延长。伴随乳腺癌患者随诊随访期的延长，患者面临的肿瘤及相关其他健康问题也逐渐增加，需要制定更为精准而长远的随诊随访计划，关注更广泛的健康风险。抗肿瘤治疗、年龄、激素水平变化等因素导致的乳腺癌患者心血管、骨健康、心理健康等问题，已成为乳腺癌患者管理的新难题，其不仅影响患者的生活质量，甚至转化为疾病复发和死亡风险。因此，除了落实规范化治疗外，患者科学规范的随诊随访、伴随疾病的全方位管理、跨学科协作、全面康复也是乳腺癌治疗的关键环节，这对于提高患者的治疗效果，提升患者健康水平和生活质量均有重大意义。基于当前中国乳腺癌患者的治疗及随诊随访现状，根据文献及指南，结合跨学科专家诊疗建议，在2019版《乳腺癌随访及伴随疾病全方位管理指南》基础上进行更新，修订2022版《中国乳腺癌随诊随访与健康管理指南》，包括随诊随访路径图、随诊随访管理、全方位健康管理以及患者报告结局四大部分，旨在规范乳腺癌患者的长期随诊随访，指导临床医师积极开展乳腺癌患者全方位跨学科健康管理，从而进一步提高中国乳腺癌患者预后与生活质量。.